Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.

Saito T, Ohnuma K, Suzuki H, Dang NH, Hatano R, Ninomiya H, Morimoto C.

Diabetes Res Clin Pract. 2013 Oct;102(1):e8-e12. doi: 10.1016/j.diabres.2013.07.010. Epub 2013 Aug 9.

PMID:
23937822
[PubMed - indexed for MEDLINE]
2.

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, Yogo M, Ogura M, Takase B, Murakami T, Ikewaki K.

J Am Heart Assoc. 2013 Jan 28;2(1):e003277. doi: 10.1161/JAHA.112.003277.

PMID:
23525426
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.

Mas-Vidal A, Santos-Juanes J, Esteve-Martinez A, Caminal-Montero L, Coto-Segura P.

Australas J Dermatol. 2012 Feb;53(1):70-2. doi: 10.1111/j.1440-0960.2011.00783.x. Epub 2011 Jun 13.

PMID:
22309337
[PubMed - indexed for MEDLINE]
4.

Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.

Yokota K, Igaki N.

Intern Med. 2012;51(15):2041-4. Epub 2012 Aug 1.

PMID:
22864134
[PubMed - indexed for MEDLINE]
Free Article
5.

Treatment with DPP-4 inhibitors does not increase the chance of pancreatitis in patients with type 2 diabetes.

Shetty AS, Nandith A, Snehalath C, Ramachandran A.

J Assoc Physicians India. 2013 Aug;61(8):543-4.

PMID:
24818338
[PubMed - indexed for MEDLINE]
6.

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA.

J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. Epub 2006 Aug 15.

PMID:
16912128
[PubMed - indexed for MEDLINE]
7.

[A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].

Abel T, Fehér J.

Orv Hetil. 2010 Jun 20;151(25):1012-6. doi: 10.1556/OH.2010.28910. Review. Hungarian.

PMID:
20519186
[PubMed - indexed for MEDLINE]
Free Article
8.

Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies.

Neumiller JJ, Odegard PS, White JR Jr, Setter SM, Campbell RK.

Diabetes Educ. 2008 Mar-Apr;34(2):183-200. doi: 10.1177/0145721708316620.

PMID:
18375772
[PubMed - indexed for MEDLINE]
9.

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A.

Diabetes Care. 2010 Jul;33(7):1607-9. doi: 10.2337/dc10-0187. Epub 2010 Mar 31.

PMID:
20357375
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

DPP-IV inhibitor-associated arthralgias.

Chaicha-Brom T, Yasmeen T.

Endocr Pract. 2013 Mar-Apr;19(2):377. No abstract available.

PMID:
23598537
[PubMed - indexed for MEDLINE]
11.

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.

Lando HM, Alattar M, Dua AP.

Endocr Pract. 2012 Jul-Aug;18(4):472-7. doi: 10.4158/EP11290.OR.

PMID:
22440997
[PubMed - indexed for MEDLINE]
12.

Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.

Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M.

Curr Drug Targets. 2009 Jan;10(1):71-87.

PMID:
19149538
[PubMed - indexed for MEDLINE]
13.

Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.

Tanaka K, Ogawa Y, Shimada S.

J Dermatol. 2012 Aug;39(8):726-8. doi: 10.1111/j.1346-8138.2011.01372.x. Epub 2011 Oct 10. No abstract available.

PMID:
21981936
[PubMed - indexed for MEDLINE]
14.
15.

DPP-IV inhibitor may affect spermatogenesis.

Hibi H, Ohori T, Yamada Y.

Diabetes Res Clin Pract. 2011 Aug;93(2):e74-5. doi: 10.1016/j.diabres.2011.04.022. Epub 2011 Jun 1.

PMID:
21636156
[PubMed - indexed for MEDLINE]
16.

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.

Stafford S, Elahi D, Meneilly GS.

J Am Geriatr Soc. 2011 Jun;59(6):1148-9. doi: 10.1111/j.1532-5415.2011.03438.x. No abstract available.

PMID:
21668924
[PubMed - indexed for MEDLINE]
17.

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.

Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ.

Curr Med Res Opin. 2009 Oct;25(10):2507-14. doi: 10.1185/03007990903209514.

PMID:
19691426
[PubMed - indexed for MEDLINE]
18.

Sitagliptin-associated drug allergy: review of spontaneous adverse event reports.

Desai S, Brinker A, Swann J, Iyasu S.

Arch Intern Med. 2010 Jul 12;170(13):1169-71. doi: 10.1001/archinternmed.2010.188. No abstract available.

PMID:
20625027
[PubMed - indexed for MEDLINE]
19.

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H.

Curr Med Res Opin. 2011 May;27(5):1049-58. doi: 10.1185/03007995.2011.568059. Epub 2011 Mar 23.

PMID:
21428727
[PubMed - indexed for MEDLINE]
20.

DPP-4 inhibitors in clinical practice.

Palalau AI, Tahrani AA, Piya MK, Barnett AH.

Postgrad Med. 2009 Nov;121(6):70-100. doi: 10.3810/pgm.2009.11.2079. Review.

PMID:
19940419
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk